The Social Responsibility Committee of the Board of Directors of Joincare has considered Access to Healthcare issues during its decision-making. It is responsible for regularly reviewing the development of the Group's strategies & policies and performance on Access to Healthcare, supervising and reporting the progress to the Board of Directors, and urging the Group to practice Access to Healthcare issues.

To improve the affordability of medicines, the Group actively responds to admission to the medical insurance list, making efforts to provide high-quality medicines to more patients at affordable prices. In addition, Joincare has been keeping track of the national centralised drug procurement, striving to be included in the national procurement list, providing fairly-priced and high-quality medicines to patients in the future.

In terms of product pricing, when entering into overseas markets, Joincare comprehensively considers the local economy, healthcare level, and price benchmarking to offer equitable pricing in line with the current regional development, avoiding an increase in the financial burden of patients. After an adequate assessment of local per capita income and analysis of local patients' affordability, differential-tiered pricing strategies were implemented for different markets. Joincare also positively goes for the bidding of local governments during product promotion in developing countries overseas so that affordable medicines and services would be offered locally. By the end of 2022, the Group and its subsidiaries have adopted equitable pricing policies in selling of 25 products in South Asia, Southeastern Asia, South America and Africa to match the local income level.

In 2022, in the new version of the National Medicine List for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (NRDL) published by the National Healthcare Security Administration, Joincare had 202 products included, among which 95 were Class A and 107 were Class B.

In 2022, two products of Joincare won the bid for the seventh batch of national procurement.

Acting upon the national policy of rural revitalisation and common prosperity, Joincare helps consolidate and expand the achievements made in poverty alleviation in coordination with the extensive drive for rural revitalisation. In particular, Joincare, by leveraging its industrial advantages, joined hands with the Group’s holding subsidiary Livzon Group to carry on the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program”. We donated drugs for treating chronic diseases, including Pravastatin Capsules (普伐他(tā)汀钠胶囊), Amlodipine Besylate Capsules (苯磺酸氨氯地平胶囊), Valsartan Capsules (缬沙坦胶囊) and Isosorbide Mononitrate Tablets (单硝酸异山(shān)梨酯片) to poor families in remote areas with chronic diseases, such as hypertension, hyperlipidemia, cardio-cerebral diseases. In doing so, we expected to reduce the medical burden of patients’ families. Since late 2018 onwards, we have carried out the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program” successively in areas including Sichuan Province, Shanxi Province, Gansu Province, Jilin Province, Tibet Autonomous Region, Henan Province, Anhui Province, Hunan Province, Jiangxi Province as part of our efforts to promote rural health. In 2022, this program was honoured as the “Top 100 Citizen Satisfaction Projects” in the 19th session of Shenzhen Project Care.

By the end of 2022, we had signed 19 agreements on the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program”, which covers 8 provinces and 1 autonomous region, including 17 remote areas in need of help, and benefiting over 6,400 patients on low income and with chronic diseases.

Joincare actively promotes cooperation with developing countries, and works with domestic and overseas pharmaceutical peers and healthcare workers to benefit patients around the world with innovative achievement and increase public health in developing countries. In addition, as an APIs supplier, Joincare shares its research results with less developed countries and regions overseas and proceeds technology transfer, and helps local pharmaceutical enterprises to improve and optimise production procedures and quality control routine by providing technology transfer and analysis and detection scheme. Therefore, the level of local production technology is increased.

Rare diseases, also known as “orphan diseases”, are featured by unknown causes and extremely low incidence rates. High treatment costs for rare diseases result from their low market demand, difficulties in R&D and lack of experience in clinical medication, and even there is high cost and no medicine for some rare diseases. We based on our own scientific platform and capabilities, undertake corporate social responsibility actively by continuously investing in research on rare diseases, and focusing on improving the current situation of diagnosis and treatment of rare diseases, thus making contributions to building a Healthy China.

Rare diseases, also known as “orphan diseases”, are featured by unknown causes and extremely low incidence rates. High treatment costs for rare diseases result from their low market demand, difficulties in R&D and lack of experience in clinical medication, and even there is high cost and no medicine for some rare diseases. Under the guidance of relevant policies such as the “Healthy China 2030” Planning Outline and the Guidelines for Diagnosis and Treatment of Rare Diseases, we, based on our own scientific platform and capabilities, undertake corporate social responsibility actively by continuously investing in research on rare diseases, and focusing on improving the current situation of diagnosis and treatment of rare diseases, thus making contributions to building a Healthy China.

By the end of 2022, Joincare has sold products and has conducted ongoing R&D in 4 orphan disease areas.